Century Therapeutics CEO Brent Pfeiffenberger forfeited 13,850 shares at $1.94 per share. The transaction left him with 3,633,839 shares and represented about 0.4% of his prior holding, giving investors the stated scale of the ownership change and the executive’s remaining position.
Key Highlights
- The transaction represented about 0.4% of Brent Pfeiffenberger’s prior share holding.
- SEC transaction code F was reported for the event.
- The share forfeiture was recorded on September 11, 2026.
Century Therapeutics, Inc. (NASDAQ: IPSC) reported a transaction involving Brent Pfeiffenberger, who forfeited 13,850 shares. The transaction was reported at $1.94 per share.
September 11 Transaction Carries Code F
The transaction date was September 11, 2026. Its SEC transaction code was F. Pfeiffenberger is Century Therapeutics’ President and CEO. The reported per-share value was tied to the 13,850 shares covered by the transaction. The ownership change concerned Pfeiffenberger’s Century Therapeutics holdings.
Forfeiture Equalled About 0.4% of Prior Holding
The transaction represented about 0.4% of Pfeiffenberger’s prior share holding. After the transaction, he owned 3,633,839 shares of Century Therapeutics. That percentage compares the forfeited shares with Pfeiffenberger’s earlier holding. The stated post-transaction balance covers his remaining shares following the ownership change. Transaction code F denotes shares withheld or delivered to cover taxes or an exercise price.
FAQs
Q: How many Century Therapeutics shares did Brent Pfeiffenberger forfeit?
A: Brent Pfeiffenberger forfeited 13,850 Century Therapeutics shares at $1.94 per share. The filing states that the transaction occurred on September 11, 2026.
Q: What percentage of Brent Pfeiffenberger’s prior holding was forfeited?
A: The transaction represented about 0.4% of Pfeiffenberger’s prior share holding. The stated percentage measures the forfeiture against his earlier position.
Q: How many shares did Pfeiffenberger own after the Century Therapeutics transaction?
A: Pfeiffenberger owned 3,633,839 Century Therapeutics shares after the transaction. The stated post-transaction balance reflects his remaining shares following the ownership change.
Download Free Report – Explore 3 Stock Ideas & Industry Insights
Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.
All investments involve risk—consider independent advice before making any investment decisions.
View 3 Research Reports
Disclaimer:
Kalkine Equities LLC, with Delaware File Number 4697384, Foreign Qualification Registration in California File Number 202109211078, and Texas File Number 805521396, is authorized to provide general advice only. The information on https://kalkine.com/ does not take into account any of your investment objectives, financial situation or needs. You should consider the appropriateness of advice taking into account your own objectives, financial situation and needs and seek independent financial advice before making any financial decisions. The link to our Terms and Conditions and Privacy Policy has been provided for your reference. On the date of publishing the reports (mentioned on the website), employees and/or associates of Kalkine do not hold positions in any of the stocks covered on the website. These stocks can change any time and readers of the reports should not consider these stocks as advice or recommendations later.